Insulin-like growth factor I peptide elution profiles from fibrin polymers determined by use of high-performance liquid chromatography

Robert L. Foley From the Comparative Orthopaedics Laboratory, Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY.

Search for other papers by Robert L. Foley in
Current site
Google Scholar
PubMed
Close
 BS
and
Alan J. Nixon From the Comparative Orthopaedics Laboratory, Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY.

Search for other papers by Alan J. Nixon in
Current site
Google Scholar
PubMed
Close
 BVSc, MS

SUMMARY

Objective

To develop a high-performance liquid chromatography (HPLC) assay for insulin-like growth factor I (IGF-I) and to use it to quantify elution of IGF-I from polymerized fibrin in an in vitro system.

Sample Population

Equine fibrinogen and calcium-activated bovine thrombin were used to form fibrin containing human recombinant IGF-I.

Procedure

Multiple fibrin disks were formed from polymerized fibrinogen and thrombin; 6 disks were loaded with 25 μg of recombinant human IGF-I at the time of polymerization, and 4 remained as unladen controls. The resultant clots were incubated at 37 C and 90% humidity for 22 days. Phosphate-buffered saline solution in each well was replaced daily, and IGF-I content was assayed by HPLC. Solid-phase separation was used to assay free IGF-I peptide peaks. A scan was done to determine optimal wavelength for IGF-I absorbance. Commercially pure IGF-I was used to construct a standard curve, and the IGF-I content of medium removed from all 10 wells each day was assayed.

Results

Pure unbound IGF-I eluted from the fibrin polymers for 22 days; initial rapid daily release of 1.6 to 1.7 μg of IGF/ml of medium changed after day 3 to commence an asymptotic decrease to 110 ng of IGF/ml by day 22. The fibrin disks had dissolved by day 22, and the experiment was terminated. Control disks did not have detectable IGF-I content at any time. Limit of the HPLC assay was 25 ng of IGF-l/ml. Retention time for nonprotein-bound IGF-I was 10.3 ± 0.15 minutes.

Conclusion

IGF-I (25 μg) can be added to polymerized fibrin and eluted as free ligand over a 22-day period of culture at 37 C. Release of IGF-I was initially independent of fibrin dissolution, but later appeared to follow a pattern consistent with fibrin degradation.

Clinical Relevance

IGF-I can be incorporated as a depot form in polymerized fibrin and is released over time in sufficient concentration to effectively stimulate articular chondrocyte metabolic activity. (Am J Vet Res 1997;58:1431–1435)

SUMMARY

Objective

To develop a high-performance liquid chromatography (HPLC) assay for insulin-like growth factor I (IGF-I) and to use it to quantify elution of IGF-I from polymerized fibrin in an in vitro system.

Sample Population

Equine fibrinogen and calcium-activated bovine thrombin were used to form fibrin containing human recombinant IGF-I.

Procedure

Multiple fibrin disks were formed from polymerized fibrinogen and thrombin; 6 disks were loaded with 25 μg of recombinant human IGF-I at the time of polymerization, and 4 remained as unladen controls. The resultant clots were incubated at 37 C and 90% humidity for 22 days. Phosphate-buffered saline solution in each well was replaced daily, and IGF-I content was assayed by HPLC. Solid-phase separation was used to assay free IGF-I peptide peaks. A scan was done to determine optimal wavelength for IGF-I absorbance. Commercially pure IGF-I was used to construct a standard curve, and the IGF-I content of medium removed from all 10 wells each day was assayed.

Results

Pure unbound IGF-I eluted from the fibrin polymers for 22 days; initial rapid daily release of 1.6 to 1.7 μg of IGF/ml of medium changed after day 3 to commence an asymptotic decrease to 110 ng of IGF/ml by day 22. The fibrin disks had dissolved by day 22, and the experiment was terminated. Control disks did not have detectable IGF-I content at any time. Limit of the HPLC assay was 25 ng of IGF-l/ml. Retention time for nonprotein-bound IGF-I was 10.3 ± 0.15 minutes.

Conclusion

IGF-I (25 μg) can be added to polymerized fibrin and eluted as free ligand over a 22-day period of culture at 37 C. Release of IGF-I was initially independent of fibrin dissolution, but later appeared to follow a pattern consistent with fibrin degradation.

Clinical Relevance

IGF-I can be incorporated as a depot form in polymerized fibrin and is released over time in sufficient concentration to effectively stimulate articular chondrocyte metabolic activity. (Am J Vet Res 1997;58:1431–1435)

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 3554 3554 1056
PDF Downloads 191 191 3
Advertisement